CRESTOR leads in 1st international prospective study of statins in the metaboli...( nt large-scale study results have shown...),Health

nt large-scale study results have shown that aggressive lipid-lowering with statins can lead to a significant reduction in heart disease deaths in patients with type 2 diabetes.¹² These new data presented at EASD demonstrate that CRESTOR 10mg is more effective than atorvastatin 10mg at improving the overall lipid profile associated with heart disease risk.

Commenting on the results, Professor Schuster of Humboldt University Berlin, lead investigator of MERCURY I explains, "Aggressively reducing LDL-C in high risk patients is becoming an increasingly important treatment strategy in the prevention of heart attacks and strokes. These results show that a low dose of CRESTOR can significantly lower LDL-C levels, therefore offering patients with type 2 diabetes an important and highly effective treatment option."

CRESTOR has now received regulatory approvals in more than 60 countries across five continents and has been launched in over 45 countries worldwide, including 13 European markets, the US and Canada. Over 2.8 million patients have been prescribed CRESTOR and more than 8 million prescriptions have been written worldwide. The post-marketing experience supports the favourable benefit:risk profile of CRESTOR and confirms that the safety profile is comparable to other currently marketed statins. CRESTOR 10mg is the usual recommended start dose for patients new to statin treatment and also for those switching to CRESTOR from other statins regardless of prior dose.

AstraZeneca is a major international healthcare business engaged in the research, development, manufacture and marketing of prescription pharmaceuticals and the supply of healthcare services. It is one of the top five pharmaceutical companies in the world with healthcare sales of over $18.8 billion and leading positions in sales of gastrointestinal, oncology, cardiovascular, neuroscience and respiratory products. AstraZeneca is listed in the Dow Jones Sustainability
'"/>

Contact: Rachael Wood
rachael.wood@astrazeneca.com
44-162-551-9514
Shire Health International
6-Sep-2004

Page: 1 2 3 4
Related medicine news :

1. 1st data show CRESTOR highly effective at lowering LDL-C in patients with type 2 diabetes
2. CRESTOR (TM) improves apolipoprotein and lipid ratios - markers of cardiovascular disease risk
3. Corrected metabolism leads to health benefits and weight loss
4. Combining PET and CT scans leads to more accurate radiation therapy for lung cancer patients
5. Lack of specific collagen type leads to osteoarthritis
6. UCI study uncovers how plaque in neck artery leads to stroke-inducing blood clots
7. Vaginal hysterectomy leads to better outcomes than abdominal surgery
8. Little evidence that breast cancer diagnosis leads to employment discrimination, study concludes
9. Marine sponge leads researchers to immune system regulator
10. Safer drug prescribing for seniors in nursing homes: Canada leads the way
11. Malnutrition in early years leads to low IQ and later antisocial behavior, USC study finds